WO2020111087A9 - 複素環化合物 - Google Patents

複素環化合物 Download PDF

Info

Publication number
WO2020111087A9
WO2020111087A9 PCT/JP2019/046261 JP2019046261W WO2020111087A9 WO 2020111087 A9 WO2020111087 A9 WO 2020111087A9 JP 2019046261 W JP2019046261 W JP 2019046261W WO 2020111087 A9 WO2020111087 A9 WO 2020111087A9
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compound
compound
cocrystal
solvate
prophylactic
Prior art date
Application number
PCT/JP2019/046261
Other languages
English (en)
French (fr)
Other versions
WO2020111087A1 (ja
Inventor
孝治 平山
吉輝 伊藤
浩 坂野
秀和 徳原
俊雄 田中
泰由 有川
紀之 新居
洋一 川北
今村　真一
Original Assignee
武田薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP19890558.0A priority Critical patent/EP3888652A4/en
Priority to IL303962A priority patent/IL303962A/en
Application filed by 武田薬品工業株式会社 filed Critical 武田薬品工業株式会社
Priority to AU2019390863A priority patent/AU2019390863A1/en
Priority to CN201980078144.XA priority patent/CN113038948A/zh
Priority to MX2021005877A priority patent/MX2021005877A/es
Priority to CA3120774A priority patent/CA3120774A1/en
Priority to BR112021009994-8A priority patent/BR112021009994A2/pt
Priority to US17/296,434 priority patent/US20220048916A1/en
Priority to SG11202105652XA priority patent/SG11202105652XA/en
Priority to KR1020227003334A priority patent/KR102646470B1/ko
Priority to JP2020557754A priority patent/JP6972384B2/ja
Priority to KR1020217019537A priority patent/KR102359143B1/ko
Publication of WO2020111087A1 publication Critical patent/WO2020111087A1/ja
Publication of WO2020111087A9 publication Critical patent/WO2020111087A9/ja
Priority to IL283368A priority patent/IL283368A/en
Priority to PH12021551251A priority patent/PH12021551251A1/en
Priority to ZA2021/04402A priority patent/ZA202104402B/en
Priority to US17/367,171 priority patent/US11230545B2/en
Priority to JP2021179627A priority patent/JP7434249B2/ja
Priority to US17/528,677 priority patent/US11897879B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

ＭＡＬＴ１阻害作用を有し得、癌等の予防または治療薬として有用であることが期待される化合物を提供すること。下式（Ｉ）： 〔式中、各記号は、明細書に記載の通りである。〕 で表される化合物またはその塩、あるいはその共結晶、水和物または溶媒和物。
PCT/JP2019/046261 2018-11-28 2019-11-27 複素環化合物 WO2020111087A1 (ja)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2020557754A JP6972384B2 (ja) 2018-11-28 2019-11-27 複素環化合物
KR1020227003334A KR102646470B1 (ko) 2018-11-28 2019-11-27 헤테로시클릭 화합물
KR1020217019537A KR102359143B1 (ko) 2018-11-28 2019-11-27 헤테로시클릭 화합물
IL303962A IL303962A (en) 2018-11-28 2019-11-27 The tricyclic compound
MX2021005877A MX2021005877A (es) 2018-11-28 2019-11-27 Compuesto heterociclico.
CA3120774A CA3120774A1 (en) 2018-11-28 2019-11-27 Heterocyclic compound
BR112021009994-8A BR112021009994A2 (pt) 2018-11-28 2019-11-27 composto, e, medicamento
US17/296,434 US20220048916A1 (en) 2018-11-28 2019-11-27 Heterocyclic compound
SG11202105652XA SG11202105652XA (en) 2018-11-28 2019-11-27 Heterocyclic compound
EP19890558.0A EP3888652A4 (en) 2018-11-28 2019-11-27 HETEROCYCLIC COMPOUND
CN201980078144.XA CN113038948A (zh) 2018-11-28 2019-11-27 杂环化合物
AU2019390863A AU2019390863A1 (en) 2018-11-28 2019-11-27 Heterocyclic compound
IL283368A IL283368A (en) 2018-11-28 2021-05-23 The tricyclic compound
PH12021551251A PH12021551251A1 (en) 2018-11-28 2021-05-28 Heterocyclic compound
ZA2021/04402A ZA202104402B (en) 2018-11-28 2021-06-25 Heterocyclic compound
US17/367,171 US11230545B2 (en) 2018-11-28 2021-07-02 Heterocyclic compound
JP2021179627A JP7434249B2 (ja) 2018-11-28 2021-11-02 複素環化合物
US17/528,677 US11897879B2 (en) 2018-11-28 2021-11-17 Heterocyclic compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-222530 2018-11-28
JP2018222530 2018-11-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/296,434 A-371-Of-International US20220048916A1 (en) 2018-11-28 2019-11-27 Heterocyclic compound
US17/367,171 Continuation US11230545B2 (en) 2018-11-28 2021-07-02 Heterocyclic compound

Publications (2)

Publication Number Publication Date
WO2020111087A1 WO2020111087A1 (ja) 2020-06-04
WO2020111087A9 true WO2020111087A9 (ja) 2021-01-21

Family

ID=70853784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/046261 WO2020111087A1 (ja) 2018-11-28 2019-11-27 複素環化合物

Country Status (15)

Country Link
US (3) US20220048916A1 (ja)
EP (1) EP3888652A4 (ja)
JP (2) JP6972384B2 (ja)
KR (2) KR102359143B1 (ja)
CN (1) CN113038948A (ja)
AU (1) AU2019390863A1 (ja)
BR (1) BR112021009994A2 (ja)
CA (1) CA3120774A1 (ja)
IL (2) IL303962A (ja)
MX (1) MX2021005877A (ja)
PH (1) PH12021551251A1 (ja)
SG (1) SG11202105652XA (ja)
TW (2) TWI784213B (ja)
WO (1) WO2020111087A1 (ja)
ZA (1) ZA202104402B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303962A (en) * 2018-11-28 2023-08-01 Takeda Pharmaceuticals Co The tricyclic compound
EP4163280A4 (en) 2020-05-27 2024-06-05 Takeda Pharmaceuticals Co METHOD FOR PREPARING A HETEROCYCLIC COMPOUND
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2023149450A1 (ja) * 2022-02-02 2023-08-10 小野薬品工業株式会社 Ｍａｌｔ１阻害薬を有効成分として含むがん治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2288521A1 (fr) * 1974-10-25 1976-05-21 Merck Patent Gmbh Nouvelles penicillines et procede pour leur preparation
EP0842933B1 (en) * 1995-05-31 2004-08-04 Sumitomo Pharmaceuticals Company, Limited Novel naphthyridine derivatives
GB9720052D0 (en) * 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
BR112016024545A2 (pt) 2014-05-28 2017-08-15 Novartis Ag derivados de pirazolo pirimidina e seu uso como inibidores de malt1
AU2016352813B2 (en) * 2015-11-13 2019-09-19 Novartis Ag Novel pyrazolo pyrimidine derivatives
KR20190033607A (ko) * 2016-07-29 2019-03-29 루핀 리미티드 Malt1 저해제로서의 치환 티아졸로-피리딘 화합물
EP3535254A4 (en) 2016-11-01 2020-06-24 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") COMPOUNDS FOR THE DEGRADATION OF MALT1
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
US20200111087A1 (en) * 2018-10-08 2020-04-09 Jinlei Zhou Method for encrypting digital contract document between contractors
IL303962A (en) * 2018-11-28 2023-08-01 Takeda Pharmaceuticals Co The tricyclic compound

Also Published As

Publication number Publication date
KR20220019848A (ko) 2022-02-17
TW202306956A (zh) 2023-02-16
TWI784213B (zh) 2022-11-21
KR102359143B1 (ko) 2022-02-08
US20220048916A1 (en) 2022-02-17
PH12021551251A1 (en) 2021-12-06
MX2021005877A (es) 2021-07-16
TW202039484A (zh) 2020-11-01
US20210332045A1 (en) 2021-10-28
US20220089595A1 (en) 2022-03-24
BR112021009994A2 (pt) 2021-08-17
IL283368A (en) 2021-07-29
AU2019390863A1 (en) 2021-06-24
AU2019390863A2 (en) 2021-07-01
US11230545B2 (en) 2022-01-25
CN113038948A (zh) 2021-06-25
US11897879B2 (en) 2024-02-13
KR20210092301A (ko) 2021-07-23
ZA202104402B (en) 2023-01-25
JPWO2020111087A1 (ja) 2021-09-27
CA3120774A1 (en) 2020-06-04
WO2020111087A1 (ja) 2020-06-04
IL303962A (en) 2023-08-01
JP2022017461A (ja) 2022-01-25
KR102646470B1 (ko) 2024-03-11
JP6972384B2 (ja) 2021-11-24
SG11202105652XA (en) 2021-06-29
JP7434249B2 (ja) 2024-02-20
EP3888652A4 (en) 2022-10-19
EP3888652A1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
WO2020111087A9 (ja) 複素環化合物
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
WO2017035353A8 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2020008754A (es) Compuestos farmaceuticos.
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
MX2017013797A (es) Inhibidor de janus quinasa.
PH12020500446A1 (en) Bisamide sarcomere activating compounds and uses thereof
MY194116A (en) Pharmaceutical compounds
CA3018932C (en) Pharmaceutical combinations for the treatment of cancer
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
ZA202307945B (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
AU2018246053A8 (en) IP6K inhibitors
MX2021012105A (es) Compuestos de pirrol.
MX2021007247A (es) Derivados de rapamicina.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2019011182A (es) Combinacion de derivados de isoindolinona con sgi-110.
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
WO2019217933A8 (en) Inhibitors of the ras oncoprotein, methods of making and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19890558

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020557754

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3120774

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021009994

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217019537

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019390863

Country of ref document: AU

Date of ref document: 20191127

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019890558

Country of ref document: EP

Effective date: 20210628

ENP Entry into the national phase

Ref document number: 112021009994

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210524